Welcome to our dedicated page for Cybin news (Ticker: CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin stock.
Cybin Inc. (symbol: CYBN) is a pioneering biopharmaceutical company dedicated to addressing mental health challenges through innovative therapeutics. Specializing in psychedelic-based therapies, Cybin focuses on developing novel compounds, delivery mechanisms, and protocols aimed at treating a range of psychiatric and neurological conditions.
Cybin's core business revolves around advancing clinical-stage programs designed to harness the potential of psychedelics. The company is engaged in creating safe and effective treatments for conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD). Their research and development efforts highlight the transformative potential of these therapies in modern medicine.
Recently, Cybin has achieved significant milestones, including progress in their proprietary drug delivery technologies. These advancements aim to improve the administration and efficacy of psychedelic compounds, ensuring patients receive the maximum therapeutic benefit. Their innovative approach extends to developing new chemical entities (NCEs) that hold promise in the field of mental health treatment.
Financially, Cybin remains robust and committed to its growth strategy. The company has secured strategic partnerships and collaborations that bolster its research initiatives and clinical trials. These alliances are crucial in accelerating the development and commercialization of their therapeutic solutions.
Cybin's product pipeline is impressive, featuring multiple candidates in various stages of development. These include CYB001, a formulation targeting major depressive disorder, and CYB003, designed for anxiety disorders. Each product undergoes rigorous testing to ensure safety and effectiveness.
In summary, Cybin Inc. is at the forefront of revolutionizing mental health treatment through psychedelic-based therapies. Their dedication to advancing science and addressing unmet medical needs positions them as a significant player in the biopharmaceutical industry.
Cybin, a biotechnology company focused on psychedelic therapeutics, announced that CEO Doug Drysdale will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. The presentation will be available on-demand starting at 7:00 AM ET and can be accessed for 90 days via the provided link. As a leader in psychedelic therapeutics, Cybin employs innovative drug discovery platforms and treatment regimens aimed at psychiatric disorders. However, all forward-looking statements are subject to risks and uncertainties.
Cybin Inc. (NYSE AMERICAN:CYBN) announced that its subsidiary, Adelia Therapeutics, has met certain milestones for Year 1 Q3 as per a December 4, 2020 agreement. In recognition, 9,392.6 Class B shares will be issued to Adelia shareholders, valued at approximately
Cybin (NEO:CYBN, AMERICAN:CYBN), a biotechnology company, has filed two international patent applications under the Patent Cooperation Treaty (PCT), potentially covering 153 countries. These applications pertain to a library of phenethylamine compounds and novel psychedelic compounds identified through research. The patents aim to strengthen the CYB005 program addressing therapy-resistant psychiatric disorders. Cybin’s drug development focuses on novel drug discovery, efficient delivery systems, and treatment regimens targeting mental health needs, including major depressive disorder and alcohol use disorder.
Cybin Inc. (NEO:CYBN) announced the filing of a new non-provisional patent application following a favorable international search report for its May 2021 PCT application. The International Patent Searching authority has validated claims within the filing, which supports the company’s pre-clinical and research programs. Cybin's portfolio now includes 14 patent filings, over 50 proprietary molecules, and 4 active drug programs targeting mental health disorders. CEO Doug Drysdale emphasized the ongoing development of the company's IP portfolio to enhance new discoveries in psychedelic therapeutics.
Cybin has announced the election of Theresa Firestone to its board of directors during a shareholder meeting on August 16, 2021. A total of 45,681,073 common shares were represented, accounting for 30.77% of total shares. Key voting results include the appointment of Zeifmans LLP as auditor with 99.76% approval, setting the board size at six directors with 99.87% approval, and amendments to the equity incentive plan with 95.43% support. Additionally, a shareholder rights plan was approved to protect shareholders during potential takeover bids.
Cybin Inc. (NEO:CYBN) reported its unaudited financial results for Q1 ended June 30, 2021. The company raised over C$120M, including C$34M in August 2021. Key highlights include becoming the first psychedelic company listed on NYSE American, initiating a digital therapeutics platform, scaling European operations, and expanding its patent portfolio to 13 filings. Cybin also commenced a collaboration with TMS NeuroHealth Centers to advance research in psychedelic therapeutics. The company reported a net loss of C$14.7 million for the quarter.
Cybin Inc. (CYBN) announces that its subsidiary Adelia Therapeutics has met key milestones as stipulated in the December 2020 Transaction Agreement. Adelia will receive Class B common shares worth approximately CAD 475,292, which can be exchanged for Cybin common shares at a 10-to-1 ratio. The Class B shares will have a staggered exchange schedule, allowing only a portion to be converted before December 2023. This development illustrates Cybin's commitment to advancing psychedelic therapeutic solutions.
Cybin (NYSE:CYBN), a biotechnology company focused on psychedelic therapeutics, has announced that CEO Doug Drysdale will present virtually at Canaccord Genuity’s 41st Annual Growth Conference on August 10, 2021, at 3:30 PM ET. The presentation will be webcast live and available for playback for 90 days following the event. Cybin is dedicated to advancing psychedelic treatments for psychiatric disorders using innovative drug discovery and delivery methods. Forward-looking statements regarding their strategic branding, capital markets exposure, and drug development programs are included in the release.
Cybin, a biotechnology company focused on psychedelic therapeutics, has announced a new partnership with Catalent, the leader in drug delivery technologies. The agreement allows Cybin to utilize Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology for its novel drug CYB003, aimed at treating resistant psychiatric disorders. This innovative delivery method promises improved pharmacokinetics by enabling pre-gastric absorption. The project begins in April 2021 with feasibility studies on various ODT formulations.
FAQ
What is the current stock price of Cybin (CYBN)?
What is the market cap of Cybin (CYBN)?
What is Cybin Inc.?
What does Cybin Inc. specialize in?
What are the core areas of Cybin's research?
What recent achievements has Cybin Inc. made?
Can you name some of Cybin's product candidates?
How does Cybin contribute to mental health treatment?
Has Cybin formed any strategic partnerships?
What is the significance of Cybin's drug delivery technologies?
What conditions are Cybin's therapies aimed at treating?
Where can I find the latest news about Cybin Inc.?
